Medicilon IncMedicilon IncMedicilon IncMedicilon Inc
  • Home
  • About
    • Medicilon Overview
    • Executive Team
    • CEO Message
    • Corporate Culture
    • Company History
    • Honor
  • Services
    • Integrated Projects
      • Antibody-Drug-Antibody (ADC)
      • Preclinical Research Services
      • IND Filing
      • Bio Drug Development
      • Chemical Drug Development
      • Chemical Compound Druggability Assessment
      • Molecular Imaging & Radiochemistry
      • OINDP Development
      • Preclinical Ophthalmic Research Platform
    • Pharmacology Services
      • Cancer Xenograft Models
      • Orthotopic Models
      • Syngeneic Mouse Models
      • Transgenic Mouse Model
      • Humanized Mouse Model (hPBMCEngrafted)
      • PDX Model
      • Digestive System Models
      • Neurological Disorders Models
      • Metabolic Disease Models
      • Inflammation & Immunological Disease Models
      • Other Disease Models
    • Chemistry Services
      • Medicinal Chemistry Services
      • Synthetic Chemistry
      • Process Development Services
      • Analytical Chemistry
    • Drug Formulation
      • Pre Formulation Development
      • Analytical Development
      • Formulation Development Services
      • Generics Consistency Evaluation
      • Research on Quality Control
      • Clinical Trial Material
      • OINDP Development
    • Biology Services
      • Discovery Biology Services
      • Recombinant Protein Services
      • Computational Biology & Molecular Modeling
      • Crystallization & Structural Determination
      • Kinase Services
      • SeMet Media Sales
    • Bioanalytical Services
      • Large Molecule Bioanalysis
      • Small Molecule Bioanalysis
    • Pharmacokinetic Services
      • In Vivo Assays
      • In Vitro Assays
    • Drug Safety Evaluation
      • Inhalation Toxicity Assessment
  • Customer
    • Customer Reviews
    • New Models of Collaboration
    • Intellectual Property Protection
    • Download Center
  • Careers
  • News
    • Medicilon Events
    • Media Coverage
    • Featured Stories
  • Contact

Blog

Home Archive by category "Medicilon Events"

Medicilon assists HitGen’s HG381 to be approved as China’s first clinical STING agonist

By medicilon | Medicilon Events | Comments are Closed | 21 April, 2021 |

On April 8, 2021, the clinical trial application of HG381 for injection, developed by HitGen, was approved by National Medical Products Administration (NMPA).  HG381 for injection is a new Category I Chemical Drug and is clinically intended to be used for the treatment of advanced tumors. HG381 is new molecular entity developed by HitGen basedRead more

Medicilon will participate 2021 AACR Virtual Annual Meeting

By medicilon | Medicilon Events | Comments are Closed | 8 April, 2021 |

#Medicilon will exhibit the 2021 AACR Virtual Annual Meeting from April 10-15.  Please visit our virtual booth for more information on our oncology and preclinical services.  We look forward to see you. #Medicilon #Oncology #DrugDiscovery #AACR21Read more

Medicilon assists Livzon Pharmaceuticals Group to obtain the clinical approval of novel coronavirus vaccine V-01

By medicilon | Medicilon Events | Comments are Closed | 29 March, 2021 |

Livzon Pharmaceutical Group Inc. (Livzon) obtained a “novel coronavirus recombinant protein vaccine” (V-01) clinical trial approval from the National Medical Products Administration (NMPA) (Batch No. 2021L90001, 2021L90002, 2021L90003).  V-01 is to prevent diseases caused by novel coronavirus infection. V-01 is an innovative novel coronavirus recombinant protein vaccine developed by Livzon and the Institute of Biophysics,Read more

Medicilon will participate 2021 SOT Virtual Annual Meeting

By medicilon | Medicilon Events | Comments are Closed | 8 March, 2021 |

Medicilon will exhibit the 2021 SOT Virtual Annual Meeting from March 12-26.  Please visit our virtual booth to meet our VPs, Dr. Frank Wang, Dr. Mingzhu Zhang, Dr. Tao Ye and Sally Tang, for more information on our toxicology services.  We look forward to see you. #Medicilon #Toxicology #DrugDiscovery #SOT2021Read more

Happy Chinese New Year

By medicilon | Medicilon Events | Comments are Closed | 10 February, 2021 |

Thank you for your business, support and partnership in 2020!  Medicilon appreciates working with you and hope that the coming year will bring you happiness and success.Read more

3D011-08 from 3D Medicines was approved of conducting clinical trials

By medicilon | Medicilon Events | Comments are Closed | 8 February, 2021 |

Jan 29th, 2021 – CDE announced that the innovative drug, 3D011-08 from 3D Medicines, was approved of conducting clinical trials. It indicates that 3D Medicines has the capacity to develop innovative drugs with global intellectual property rights, which has laid a solid foundation for the achievement of the company’s long-term sustainable development strategic goals. 3D011Read more

Xuanzhu Biotech Announced the Clinical Trial Approval of XZP-5610

By medicilon | Medicilon Events | Comments are Closed | 8 February, 2021 |

Jan.27, 2021 – Xuanzhu Biotech announced that their XZP-5610, a new treatment for NASH (non-alcoholic steatohepatitis), was approved of clinical trials by China NMPA. XZP-5610 was the 14th innovative medicine that was approved of clinical trials. XZP is one small molecule agonist with high efficiency, high selectivity and novel structure that can significantly improve theRead more

Medicilon was Awarded the Excellent Academician and Expert Workstation of Shanghai and Pudong New Area

By medicilon | Medicilon Events | Comments are Closed | 13 January, 2021 |

Recently, Shanghai Medicilon was awarded the title of “Excellent Expert Workstation” by the Shanghai Academician and Expert Workstation Guidance Office and the title of “2020 Pudong New Area Excellent Academician and Expert Workstation” by the Pudong Science and Technology Association. Medicilon was awarded the title of “Excellent Expert Workstation” by the Shanghai Academician Expert WorkstationRead more

Medicilon’s Top 10 Greatest Achievements in 2020

By medicilon | Medicilon Events | Comments are Closed | 4 January, 2021 |

You may say that the Coronavirus Pandemic will define 2020. You may say that 2020 has given us more than our fair share of challenges and obstacles. But that doesn’t mean great achievements in 2020 didn’t occur! Medicilon embodies its motto of being “Innovation-driven, quality-focused” and keeps on maintaining and improving its technology and qualityRead more

Medicilon’s pharmacology models for inflammatory-immune diseases

By medicilon | Featured Stories, Medicilon Events | Comments are Closed | 1 January, 2021 |

Inflammatory immune diseases have gained much attention as the incidence has grown bigger each year. The diseases can affect many parts of human bodies and reduce the quality of life drastically. Yet the diagnoses can be frustrating and stressful because no one is sure what causes such diseases. The preclinical pharmacology department of Medicilon hasRead more

123

About Us

  • Medicilon Overview
  • Executive Team
  • Company History
  • CEO Message
  • Honor
  • Customer Reviews
  • New Models of Collaboration
  • Intellectual Property Protection
  • Corporate Culture
  • Careers
  • Download Center
  • Contact

Share

About Us

  • Medicilon Overview
  • Executive Team
  • CEO Message
  • Company History
  • Corporate Culture
  • Honor

Services

  • Chemistry
  • Biology
  • Bioanalytical
  • Drug Safety Evaluation
  • Formulation Development
  • Pharmacology
  • Pharmacokinetic
  • Integrated Projects

Customer Center

  • Customer Reviews
  • Download Center
  • Intellectual Property Protection
  • New Models of Collaboration

Contact Us

Shanghai Medicilon Inc.

Address: No. 585, Chuanda Road, Pudong, Shanghai, 201200, China
Email: Marketing@medicilon.com
Website: www.medicilon.com

Copyright 2017 Shanghai Medicilon inc. | All Rights Reserved Privacy Policy
  • Languages
  • 中国日本대한민국
  • Home
  • About
    • Medicilon Overview
    • Executive Team
    • CEO Message
    • Corporate Culture
    • Company History
    • Honor
  • Services
    • Integrated Projects
      • Antibody-Drug-Antibody (ADC)
      • Preclinical Research Services
      • IND Filing
      • Bio Drug Development
      • Chemical Drug Development
      • Chemical Compound Druggability Assessment
      • Molecular Imaging & Radiochemistry
      • OINDP Development
      • Preclinical Ophthalmic Research Platform
    • Pharmacology Services
      • Cancer Xenograft Models
      • Orthotopic Models
      • Syngeneic Mouse Models
      • Transgenic Mouse Model
      • Humanized Mouse Model (hPBMCEngrafted)
      • PDX Model
      • Digestive System Models
      • Neurological Disorders Models
      • Metabolic Disease Models
      • Inflammation & Immunological Disease Models
      • Other Disease Models
    • Chemistry Services
      • Medicinal Chemistry Services
      • Synthetic Chemistry
      • Process Development Services
      • Analytical Chemistry
    • Drug Formulation
      • Pre Formulation Development
      • Analytical Development
      • Formulation Development Services
      • Generics Consistency Evaluation
      • Research on Quality Control
      • Clinical Trial Material
      • OINDP Development
    • Biology Services
      • Discovery Biology Services
      • Recombinant Protein Services
      • Computational Biology & Molecular Modeling
      • Crystallization & Structural Determination
      • Kinase Services
      • SeMet Media Sales
    • Bioanalytical Services
      • Large Molecule Bioanalysis
      • Small Molecule Bioanalysis
    • Pharmacokinetic Services
      • In Vivo Assays
      • In Vitro Assays
    • Drug Safety Evaluation
      • Inhalation Toxicity Assessment
  • Customer
    • Customer Reviews
    • New Models of Collaboration
    • Intellectual Property Protection
    • Download Center
  • Careers
  • News
    • Medicilon Events
    • Media Coverage
    • Featured Stories
  • Contact
Medicilon Inc